News - Anti-Arthritics/Rheumatics

Filter

Popular Filters

101 to 125 of 297 results

Third milestone for Neovacs in the Tracker program for rheumatoid arthritis

13-05-2013

French biotech firm Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment…

Anti-Arthritics/RheumaticsBiotechnologyFinancialNeovacsResearch

Novartis' Ilaris gets new indication of childhood arthritis from US FDA

10-05-2013

Swiss pharmaceutical major Novartis (NIVN: VX) said this morning (May 10) that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsNorth AmericaPharmaceuticalRare diseasesRegulation

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Merck & Co wins Fosamax federal bellwether trial over atypical femur fracture claims

30-04-2013

A US has jury found in favor of pharma giant Merck & Co (NYSE: MRK) in the Glynn versus Merck case in…

Anti-Arthritics/RheumaticsFosamaxLegalMerck & CoNorth AmericaPharmaceutical

EMA committee gives thumbs down for Pfizer's Xeljanz for RA

26-04-2013

Shares of Pfizer (NYSE: PFE) fell 2.4% to $29.53 in extended New York trading yesterday, after the pharma…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationXeljanz

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

New Zealand considers listing of Neulastim and Actemra

12-04-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…

ActemraAnti-Arthritics/RheumaticsAsia-PacificBiotechnologyNeulastimOncologyPharmaceuticalPricingRegulationRoche

Thought leader views on new osteoporosis and osteopenia treatments

05-04-2013

US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

Mixed top-line results for AstraZeneca's RA drug candidate fostamatinib

05-04-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning reported top-line results from the Phase…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibPharmaceuticalResearch

AbbVie's Humira cleared in EU for polyarticular juvenile idiopathic arthritis

03-04-2013

The European Commission has approved an extension of the European Union marketing authorization for US…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulation

Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA

03-04-2013

According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

BioTrends views Xeljanz and Zytiga prescribing in USA

26-03-2013

After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

NPS Pharma regains rights to Revestive and Preotact from Takeda

20-03-2013

USA-based NPS Pharmaceuticals (Nasdaq: NPSP) has re-gained the full worldwide rights from partner Takeda…

Anti-Arthritics/RheumaticsGastro-intestinalsGattexLicensingNatparaNPS PharmaceuticalsPharmaceuticalPreotactRevestiveTakeda Pharmaceuticals

Roche's RoActemra shows superiority to Humira in rheumatoid arthritis

18-03-2013

Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug…

Anti-Arthritics/RheumaticsBiotechnologyHumiraPharmaceuticalResearchRoActemraRoche

Merck Serono collaborates with Nordic Bioscience for sprifermin in osteoarthritis

18-03-2013

German drug and chemical major Merck KGaA (MRK: DE) says its Merck Serono division has entered into a…

Anti-Arthritics/RheumaticsMerck KGaAMerck SeronoNordic BiosciencePharmaceuticalResearchsprifermin

Switch to anabolics driving osteoporosis market growth

11-03-2013

A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency

11-03-2013

Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

NICE green light for earlier use of Bristol-Myers' Orencia

08-03-2013

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) now recommends…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalRegulation

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015

06-03-2013

Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

101 to 125 of 297 results

Company Spotlight

Fibrotech

Fibrotech

Back to top